# Junta clínica — PT-pseudo_e9fbcdc890f2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e9fbcdc890f2",
  "pid": "PT-pseudo_e9fbcdc890f2",
  "task": 1,
  "psa": 82.0,
  "age": 74,
  "months": 2,
  "pirads": "5",
  "psad": 1.281,
  "psav": 9.76,
  "psap": 62.9,
  "vol": 64.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.9339169,
  "medhx": "Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis",
  "meds": "amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN",
  "notes": "PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "96 kg",
    "height": "185 cm",
    "bmi": "28.0",
    "bp": "139/80 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy."
    },
    {
      "s": "History",
      "t": "A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "self-employed contractor (carpentry)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "39 units / week (heavy)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e9fbcdc890f2
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 82.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 1.281 ng/mL²
  - PSA velocity: 9.76 ng/mL/yr
  - Prior PSA: 62.9 ng/mL
  - Prostate volume: 64.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9339169 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.

Vitals: weight 96 kg, height 185 cm, BMI 28.0, BP 139/80 mmHg, HR 72 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2023).

Chief complaint: Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy.

History: A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support.

Physical examination: DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses.

Patient info: self-employed contractor (carpentry); Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 39 units / week (heavy); exercise Running 3x/week, 5 km; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.13 epistemic (95% band 0.29-0.82); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 4 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 74 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 82 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 64 mL (1% of my signal; from log_vol, vol) · PSA density = 1.281 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.93 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 82 ng/mL
  important  prior biopsy = Positive
  noted      age = 74 · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · PI-RADS = 5 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 49 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.23: PI-RADS 5, PSA 70.0, PSAD 0.67, age 68, DRE Normal -> DEFER (clear). He wrote: "This patient has PCa and a very high PSA. start treatment and do a PSMA-PET ."
  2. distance 2.08: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 2.08: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive · PSA = 82 ng/mL · PI-RADS = 5
  noted      age = 74 · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive · PI-RADS = 5
  important  age = 74 · PSA = 82 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · comorbidity = 4 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that the decision to perform a biopsy should be guided by a risk-adapted approach, considering the PI-RADS score and PSA density. The retrieved text states, "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]." This requires assessing the patient's PSA density against these thresholds to guide the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is decisive, whereas the guideline treats this as context. The guideline requires assessing the patient's PSA density against the thresholds to guide the decision. The fact the guideline needs that no panel variable represents is the PSA density value, which is not represented by any expert as decisive.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: Positive means the guideline suggests staging and treatment, not more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the trend is not explicitly detailed in the retrieved document, so the guideline requires the trend to assess risk.
laboratory_results - the PSA density: the PSA density value is crucial as it is a key variable in the guideline's risk-adapted matrix.
family-history anamnesis - the family history of prostate cancer is needed to assess risk factors as per the guideline.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the prior positive biopsy mandates a shift to treatment planning as per the cohort criterion, or if the PI-RADS 5 and PSA density require further tissue sampling according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA trend, as required by the EAU guideline to assess risk?
  previous_notes (get_previous_notes) -> What is the GRADE of the prior biopsy, the number and dates of biopsy sessions, whether the patient is on a SURVEILLANCE protocol with a confirmatory biopsy due, and whether a TREATMENT is already agreed or declined?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What should be done given the PSA = 82 ng/mL?
  Q2. What should be done given the prior biopsy = Positive?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates that the lesion is compared against an earlier study: "Post-contrast phases demonstrate prompt, focal hyperenhancement compared to adjacent tissue."
psa_trend
The PSA trend is: "PSA 2.0 (Jan 2023) rising to 82.0 (Feb 2025), steepest in the last year."
previous_notes
The GRADE of the prior biopsy is not explicitly stated, but there is one note from "Dr. F. de Boer (GP)" dated "05 Sep 2023" stating: "Following a July PSA reading of 40.6 ng/mL—a concerning upward trend from the 42.3 ng/mL documented earlier in the year—the patient was forwarded to the urology outpatient clinic for further workup and potential biopsy consideration." There is no mention of a SURVEILLANCE protocol or agreed treatment.

WHAT I DID NOT OPEN
laboratory_results and family-history anamnesis were left closed because they were not explicitly required by the Moderator's list of open questions, and opening them would not change the immediate decision point based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI report shows a PI-RADS 5 lesion, which is a high-risk feature.
The PSA trend shows a steep rise, culminating in a PSA of 82.0 ng/mL.
AGAINST sampling this patient now
The previous notes suggest a prior biopsy consideration but do not explicitly state the final GRADE or current surveillance status.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 82.00 ng/mL over 5 points spanning 25 months; velocity +32.39 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 105.0 ng/mL, conformal 95% band 30.1-365.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 82 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.70), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 82 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 64 mL (4% of my signal; from log_vol, vol) · PSA density = 1.281 (0% of my signal; from psad_calc) · comorbidity = 4 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.48  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.27  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          74                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          82 ng/mL                     E1:not E3:not cohort:DEC library:DEC E2:not          -> important
  vol          64 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         1.281                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.93                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> decisive
  comorbidity  4 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) address the moderator's questions to some extent, particularly regarding the PSA trend and the context of the prior biopsy consideration.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PSA $\ge$ 20 ng/mL) fired, which is the rule that carried the most weight in the protocol.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What should be done given the PSA = 82 ng/mL? The PSA trend shows a steep rise, which is a factor, but the panel protocol's decision is based on the cohort criterion.
Q2. What should be done given the prior biopsy = Positive? The previous notes indicate prior biopsy consideration but lack a final GRADE, which is a point of uncertainty.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 82 ng/mL, because the cohort criterion (PSA $\ge$ 20 ng/mL) was decisive in the panel protocol.
prior biopsy: decisive: Positive, because this variable was decisive for the cohort criterion, leading to the panel's decision.
age: important: 74, as it was noted by multiple experts, contributing to the overall context.
MY SUGGESTION TO THE CHAIR
I suggest deferring the biopsy, as the PANEL-PROTOCOL's answer rests on the cohort criterion, which was triggered by the PSA value, despite the conflicting expert opinions.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

74 y/o male, PSA 82.0 ng/mL, PSAD 1.281, PI-RADS 5, prior positive biopsy. High PSA and known cancer status dictate staging and treatment over repeat biopsy. The PI-RADS 5 finding is expected given the known diagnosis, and no prior biopsy grade is recorded.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
